Accustem Sciences Inc Quick Ratio (ACUT) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Accustem Sciences Inc   (ACUT)

Accustem Sciences Inc 's Quick Ratio

ACUT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0 a new company low.

Within Major Pharmaceutical Preparations industry 450 other companies have achieved higher Quick Ratio than Accustem Sciences Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 4038 to 4473.

Explain Quick Ratio?
How much Cash & cash equivalents ACUT´s has?
What are ACUT´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ACUT Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 37.98 % 46.26 % 47.17 % 35.99 % 37.18 %
Y / Y Cash & cash equivalent Change -58.75 % -66.45 % 176.04 % -61.19 % -31.97 %
Quick Ratio MRQ 0 0 0 0 0.01
ACUT's Total Ranking # 4473 # 4038 # 4411 # 3688 # 3716
Seq. Current Liabilities Change 5.57 % 9.51 % 10.41 % 8.1 % 11.9 %
Seq. Cash & cash equivalent Change 5.91 % -12.36 % -3.21 % -54.08 % -13.85 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 451
Healthcare Sector # 917
Overall Market # 4473


Quick Ratio Statistics
High Average Low
5.78 0.62 0
(Mar 31 2022)   (Dec 31 2024)




Financial Statements
Accustem Sciences Inc 's Current Liabilities $ 6 Millions Visit ACUT's Balance sheet
Accustem Sciences Inc 's Cash & cash equivalent $ 0 Millions Visit ACUT's Balance sheet
Source of ACUT's Sales Visit ACUT's Sales by Geography


Cumulative Accustem Sciences Inc 's Quick Ratio

ACUT's Quick Ratio for the trailling 12 Months

ACUT Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 41.77 % 41.91 % 39.93 % 39.74 % 62.18 %
Y / Y Cash & cash equivalent TTM Growth -51.34 % -42.31 % -1.57 % -23.55 % -25.74 %
Quick Ratio TTM 0 0 0.01 0.01 0.01
Total Ranking TTM # 4199 # 3219 # 3174 # 3446 # 3118
Seq. Current Liabilities TTM Growth 8.29 % 9.92 % 10.11 % 8.17 % 8.39 %
Seq. Cash & cash equivalent TTM Growth -25.62 % -25.17 % 10.19 % -20.65 % -11.82 %

Quick ratio ranking by company, industry and sector >> Back to ACUT Financial Strength Comparisons >> Go to Compare ACUT Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the rise in Current Liabilities in the Q2 2026 to $5.72 millions, cumulative Quick Ratio